Detalhe da pesquisa
1.
Time interval between diagnosis to treatment of breast cancer and the impact of health insurance coverage: a sub analysis of the AMAZONA III Study (GBECAM 0115).
Breast Cancer Res Treat
; 198(1): 123-130, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36586038
2.
The impact of sociodemographic factors and health insurance coverage in the diagnosis and clinicopathological characteristics of breast cancer in Brazil: AMAZONA III study (GBECAM 0115).
Breast Cancer Res Treat
; 183(3): 749-757, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32728860
3.
Prevalence and risk factors of medication-related osteonecrosis of the jaw in osteoporotic and breast cancer patients: a cross-sectional study.
Support Care Cancer
; 28(5): 2265-2271, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-31468192
4.
Planning cancer control in Latin America and the Caribbean.
Lancet Oncol
; 14(5): 391-436, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23628188
5.
Real-World Evidence of Ribociclib Plus Aromatase Inhibitors as First-Line Treatment in Advanced Breast Cancer: The BrasiLEEira Study.
JCO Glob Oncol
; 10: e2300484, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38603658
6.
Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experience.
Oncologist
; 18(2): 134-40, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23359433
7.
Breast cancer in Brazil: present status and future goals.
Lancet Oncol
; 13(3): e95-e102, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22381937
8.
Cost-effectiveness of ribociclib for premenopausal or perimenopausal women with HR+/HER2- advanced breast cancer: a Brazilian public health care system perspective.
Ther Adv Med Oncol
; 14: 17588359221100865, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36339925
9.
Optimizing treatment selection, and sequencing decisions for Management of HR-Positive, HER2-Negative advanced breast cancer - Proceedings from breast cancer expert group meeting.
BMC Proc
; 15(Suppl 10): 15, 2021 Aug 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34372853
10.
Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE.
J Clin Oncol
; 39(1): 79-89, 2021 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32822287
11.
Further evidence of the prognostic role of pretreatment levels of CA 19-9 in advanced pancreatic cancer.
Rev Assoc Med Bras (1992)
; 56(1): 22-6, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-20339781
12.
Optimizing the management of HER2-negative metastatic breast cancer in the era of PARP inhibitors-proceedings from breast cancer expert group meeting.
Chin Clin Oncol
; 9(5): 61, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32819114
13.
Cross-Cultural Validity Study of a Medical Education Leadership Competencies Instrument in Latin American Physicians: A Multinational Study.
J Glob Oncol
; 5: 1-9, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31770067
14.
Advanced Stage at Diagnosis and Worse Clinicopathologic Features in Young Women with Breast Cancer in Brazil: A Subanalysis of the AMAZONA III Study (GBECAM 0115).
J Glob Oncol
; 5: 1-10, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31730380
15.
Characteristics and prognosis of stage I-III breast cancer subtypes in Brazil: The AMAZONA retrospective cohort study.
Breast
; 44: 113-119, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30738289
16.
Incidental Findings in Reduction Mammoplasty Specimens in Patients with No Prior History of Breast Cancer. An Analysis of 783 Specimens.
Pathol Oncol Res
; 24(1): 95-99, 2018 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-28391513
17.
Efficient Synthesis of Glutamate Peptide-Estradiol Conjugate for Imaging Estrogen Receptor-Positive Diseases.
Biomed Res Int
; 2018: 5208964, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30356372
18.
Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE.
J Clin Oncol
; 36(8): 741-748, 2018 03 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29244528
19.
The germline mutational landscape of BRCA1 and BRCA2 in Brazil.
Sci Rep
; 8(1): 9188, 2018 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29907814
20.
Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial.
J Clin Oncol
; 35(13): 1421-1429, 2017 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28375706